HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Annovis Bio (NYSE:ANVS) and maintained a price target of $30.
October 16, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Annovis Bio and maintained a $30 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $30 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Annovis Bio's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100